Skip to search formSkip to main contentSkip to account menu

olokizumab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The anti-IL-6 tocilizumab is a recognized treatment in rheumatoid arthritis and in systemic juvenile idiopathic arthritis. Almost… 
2016
2016
Background Olokizumab (OKZ) is an anti-interleukin-6 (IL-6) monoclonal antibody in development for the treatment of rheumatoid… 
2016
2016
Background Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life… 
2013
2013
Objectives Tocilizumab (TCZ) is a humanized monoclonal antibody against the α-chain of the IL6 receptor. In clinical trials TCZ…